Autopsy report · NCT03397446
Lisdexamfetamine for Adults With Bulimia Nervosa
Cause of deathFunding or business, also safety
“Loss of resources due to COVID-19 resulted in insufficient funds to complete the trial as planned. However, sufficient data was collected to fulfill the aims of the trial. Discontinuation is not related to the drug, its use, or adverse events.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 1 year 11 months before it stopped.
- 23 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Aaron Keshen
- Sponsor type
- University, hospital or other
- Conditions
- Bulimia Nervosa
- Interventions
- Lisdexamfetamine dimesylate
- Participants
- 23
- Sites
- 1
- Countries
- Canada
Trials that died the same way
- Evaluating Emetine for Viral Outbreaks (EVOLVE)
“The study was terminated due to insufficient participant enrollment resulting from a lower-than-expected number of COVID-19 cases” - Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D
“Withdrawn due to COVID-19 related clinical limitations” - Fecal Microbiota Transplant for Primary CDI
“The study was terminated after a covid-related suspension and the unavailability of drug.” - PERSEUS-PS Randomized Controlled Trial
“The trial prematurely terminated as a result of the COVID-19 pandemic.” - A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
“The study was terminated early due to low enrollment and missing efficacy assessment data due to missed visits related to COVID-19.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.